CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
CohBar, Inc. (CWBR) faces delisting from Nasdaq due to non-compliance with certain board and committee composition listing requirements and filing requirements. The company does not plan to request a hearing and expects trading in its common stock to be suspended on November 29, 2023.
Negative
Facing delisting from Nasdaq due to non-compliance with listing and filing requirements
11/27/2023 - 06:05 PM
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
MENLO PARK, Calif. --(BUSINESS WIRE)--
On November 20, 2023, CohBar, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff’s belief that the Company is a “public shell,” and that the continued listing of the Company’s securities is no longer warranted, and the Company’s non-compliance with certain board and committee composition listing requirements under Nasdaq Listing Rule 5605 and certain of Nasdaq’s filing requirements under Nasdaq Listing Rule 5250(c)(1), trading of the Company’s common stock will be suspended at the opening of business on November 29, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel to appeal Nasdaq’s determination and address the deficiencies. The Company does not plan to request a hearing and expects that trading in the Company’s common stock will be suspended upon the opening of business on November 29, 2023. Thereafter, Nasdaq will file a Form 25-NSE with the SEC to formally delist the Company’s common stock. Nasdaq has not specified the exact date on which the Form 25-NSE will be filed.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231127359445/en/
Craig R. Jalbert, President of CohBar, Inc., +1 508-543-1720 or cohbar@vlpc.com
Source: CohBar, Inc.
Why is CohBar, Inc. (CWBR) facing delisting from Nasdaq?
The company is facing delisting due to non-compliance with certain board and committee composition listing requirements and filing requirements.
When will trading in CohBar, Inc. (CWBR) common stock be suspended?
Trading in the company's common stock is expected to be suspended on November 29, 2023.
Will CohBar, Inc. (CWBR) request a hearing to appeal Nasdaq's determination?
The company does not plan to request a hearing to appeal Nasdaq's determination.
CWBR Rankings
N/A Ranked by Stock Gains
CWBR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
About CWBR
cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
